What is GentiBio?
GentiBio is a biotherapeutics innovator established in 2020 and headquartered in Boston, Massachusetts. The company is dedicated to developing engineered regulatory T cells designed to treat a spectrum of challenging conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. By leveraging advanced cell programming, GentiBio aims to offer precise and effective therapeutic interventions for patients with significant unmet medical needs.
How much funding has GentiBio raised?
GentiBio has raised a total of $157M across 1 funding round:
Series A
$157M
Series A (2021): $157M with participation from JDRF T1D Fund, Avidity Partners, RA Capital Management, Matrix Capital Management, and OrbiMed
Key Investors in GentiBio
JDRF T1D Fund
The JDRF T1D Fund is a venture impact fund focused on accelerating treatments and cures for Type 1 Diabetes, strategically investing in innovative therapies and disease modification.
RA Capital Management
RA Capital Management is a multi-stage investment firm specializing in healthcare and life sciences, with a focus on public and private companies developing drugs, medical devices, and diagnostics.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
What's next for GentiBio?
The substantial enterprise-level funding and strategic investment indicate GentiBio is poised for significant scaling and further development of its proprietary cell therapy platform. This capital infusion will likely accelerate clinical trials, expand research and development capabilities, and bolster the company's operational infrastructure. The company's focus on complex immunological diseases suggests a long-term vision for transforming patient care in these areas.
See full GentiBio company page
